China Biologic Products, Inc. (NASDAQ:CBPO)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group LLC in a research note issued to investors on Friday.

CBPO has been the topic of several other reports. Zacks Investment Research downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Friday, May 5th. BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Finally, Goldman Sachs Group, Inc. (The) initiated coverage on shares of China Biologic Products in a research note on Tuesday, May 30th. They issued a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $132.00.

Shares of China Biologic Products (CBPO) opened at 97.04 on Friday. China Biologic Products has a 12-month low of $96.00 and a 12-month high of $137.38. The stock has a 50 day moving average of $105.95 and a 200-day moving average of $108.21. The company has a market capitalization of $2.64 billion, a P/E ratio of 25.13 and a beta of 1.70.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.05. The firm had revenue of $89.28 million for the quarter, compared to the consensus estimate of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same period last year, the firm posted $1.26 earnings per share. Equities research analysts forecast that China Biologic Products will post $4.95 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/05/china-biologic-products-cbpo-buy-rating-reaffirmed-at-jefferies-group-llc.html.

In other China Biologic Products news, insider Zhijing Cbpo Liu sold 7,500 shares of China Biologic Products stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $116.49, for a total transaction of $873,675.00. Following the transaction, the insider now directly owns 10,969 shares of the company’s stock, valued at $1,277,778.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.73% of the stock is owned by insiders.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after buying an additional 1,318,183 shares during the period. FMR LLC increased its position in shares of China Biologic Products by 27.5% in the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock worth $188,300,000 after buying an additional 406,105 shares during the period. Hermes Investment Management Ltd. increased its position in shares of China Biologic Products by 91.6% in the first quarter. Hermes Investment Management Ltd. now owns 631,224 shares of the biopharmaceutical company’s stock worth $63,204,000 after buying an additional 301,828 shares during the period. Macquarie Group Ltd. purchased a new position in shares of China Biologic Products during the first quarter worth approximately $27,324,000. Finally, Artisan Partners Limited Partnership increased its position in shares of China Biologic Products by 103.2% in the first quarter. Artisan Partners Limited Partnership now owns 395,578 shares of the biopharmaceutical company’s stock worth $39,609,000 after buying an additional 200,868 shares during the period. 74.24% of the stock is currently owned by institutional investors.

About China Biologic Products

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.